Some individuals may notice an immediate boost, while for others, the effects develop more gradually
10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with obesity or overweight in Phase 3 trial In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1 The trial met both weight loss primary endpoints and its key secondary endpoint evaluating waist circumference, a predictor of cardiometabolic risk, together demonstrating survodutide's potential to broadly improve metabolic health1 In addition to these positive results, Boehringer is advancing its broad metabolic health R&D program, exploring multiple pharmaceutical approaches to weight management including oral treatments
Creatine Olimp Best Sellers Omega 3 Performance Support Sports Nutrition Testosterone Boosters Vitamins & Wellness Olimp Ashwagandha 600 Sport 60 Capsules Olimp Born in The Gym Online Store Gift Card Olimp Creatine Monohydrate Powder 8.82 oz (250 g) Olimp Gold Omega 3 Sport Edition 120 Capsules
Taken together, these findings suggest that EV-derived VDAC1 protein might enhance PTX resistance in GC cells by modulating general autophagy and mitophagy, an effect that is attenuated when EV-derived VDAC1 levels are decreased
Tanshinone IIA (TIIA) enhances NRF2 binding and transcriptional activation at the promoters of target transporter proteins BSEP and NTCP through TET2-mediated demethylation of NRF2
The determined cryo-EM structure of human RNF213 and the crystal structure of the IpaH1.4 LRR/RNF213 RING complex elucidate the molecular mechanism by which IpaH1.4 specifically target RNF213
